Loading...

Neil Pravin Shah, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, MSB
San Francisco CA 94117
Phone415-514-0269
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California Los AngelesM.D.1996School of Medicine
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Research 
    Collapse Research Activities and Funding
    Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.
    NIH R41CA199753Sep 23, 2015 - Aug 31, 2016
    Role: Principal Investigator
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    NIH R01CA194094Aug 1, 2015 - Jul 31, 2019
    Role: Principal Investigator
    Crenolanib and ponatinib for the treatment of FLT3 mutant AML
    NIH R01CA176091Apr 8, 2013 - Mar 31, 2018
    Role: Principal Investigator
    Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML
    NIH R01CA166616Apr 17, 2012 - Mar 31, 2017
    Role: Principal Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021 Feb; 9(2). PMID: 33568350.
      View in: PubMed   Mentions:    Fields:    
    2. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. J Clin Oncol. 2020 Sep 20; 38(27):3088-3094. Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI. PMID: 32491962.
      View in: PubMed   Mentions: 1     Fields:    
    3. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019 12 17; 7(1):353. Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. PMID: 31847881.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    4. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. Br J Cancer. 2019 11; 121(10):827-836. Hutchison IL, Ridout F, Cheung SMY, Shah N, Hardee P, Surwald C, Thiruchelvam J, Cheng L, Mellor TK, Brennan PA, Baldwin AJ, Shaw RJ, Halfpenny W, Danford M, Whitley S, Smith G, Bailey MW, Woodwards B, Patel M, McManners J, Chan CH, Burns A, Praveen P, Camilleri AC, Avery C, Putnam G, Jones K, Webster K, Smith WP, Edge C, McVicar I, Grew N, Hislop S, Kalavrezos N, Martin IC, Hackshaw A. PMID: 31611612.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    5. Product review on the Anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother. 2018 02 01; 14(2):269-276. Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A. PMID: 29194007.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Assessing Screening Guidelines for Cardiovascular Disease Risk Factors using Routinely Collected Data. Sci Rep. 2017 07 26; 7(1):6488. Pannu J, Poole S, Shah N, Shah NH. PMID: 28747722.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    7. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Ann Hematol. 2017 Aug; 96(8):1303-1313. Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. PMID: 28534184.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. PMID: 27956535.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    9. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74. Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. PMID: 27192969.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    10. Cow's Milk Allergy Prescribing Is Influenced by Regional and National Guidance. J Pediatr Gastroenterol Nutr. 2016 05; 62(5):765-70. Wauters L, Brown T, Venter C, Dziubak R, Meyer R, Brogan B, Walsh J, Fox AT, Shah N. PMID: 26628440.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    11. PPAR?: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411. Apsel Winger B, Shah NP. PMID: 26461088.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    12. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep. 2015 Sep 30; 5:14538. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. PMID: 26419724.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    13. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. PMID: 25847190.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    14. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. PMID: 25456130.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    15. Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia. ACS Nano. 2014 Sep 23; 8(9):9199-208. PMID: 25166742.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    16. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. PMID: 24374145.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    17. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013 Nov; 163(4):514-9. Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. PMID: 24111495.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    18. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. PMID: 20131302.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    19. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. PMID: 20139391.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    20. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. PMID: 19804904.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    21. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. PMID: 19536906.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    22. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009 Mar 15; 69(6):2384-92. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. PMID: 19276351.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    23. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 09; 14(6):485-93. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. PMID: 19061839.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansCells
    24. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 01; 26(19):3204-12. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. PMID: 18541900.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCTClinical Trials
    25. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. PMID: 18401416.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    26. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S31-S36. Shah NP. PMID: 18397679.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    27. Progressive thoughts about progressive disease. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5229-31. Shah NP. PMID: 17875748.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    28. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007 Sep; 117(9):2562-9. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. PMID: 17710227.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansAnimalsCells
    29. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15; 109(12):5143-50. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. PMID: 17317857.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    30. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 2007 Apr 15; 109(8):3400-8. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB. PMID: 17209055.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    31. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007; 371-5. Shah NP. PMID: 18024653.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    32. Dasatinib. Drugs Today (Barc). 2007 Jan; 43(1):5-12. Shah NP. PMID: 17315048.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    33. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15; 109(8):3207-13. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. PMID: 17185463.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    34. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303-9. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. PMID: 17138817.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansCTClinical Trials
    35. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. PMID: 16477019.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    36. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006 Jan 15; 66(2):1007-14. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. PMID: 16424036.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    37. Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. PMID: 15988530.
      View in: PubMed   Mentions: 249     Fields:    Translation:HumansCells
    38. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005; 183-7. Shah NP. PMID: 16304378.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    39. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005 Mar 01; 105(5):2093-8. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. PMID: 15345592.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    40. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16; 305(5682):399-401. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. PMID: 15256671.
      View in: PubMed   Mentions: 440     Fields:    Translation:HumansAnimalsCells
    41. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003 Oct 20; 22(47):7389-95. Shah NP, Sawyers CL. PMID: 14576846.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    42. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002 Aug; 2(2):117-25. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. PMID: 12204532.
      View in: PubMed   Mentions: 471     Fields:    Translation:HumansCells
    43. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10700-5. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. PMID: 12149456.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    Neil Pravin's Networks
    Concepts (247)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑